Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42214 | 0.98 | CYP1A2 (0.46) | CYP1A2CHRM5ADRA2CHRH3SIRT2 | |
| SCHEMBL8587237 | 0.84 | CYP1A2 (0.50) | CYP1A2CHRM5ADRA2CHRH3DRD2 | |
| SCHEMBL9431697 | 0.82 | DRD2 (0.38) | DRD2DRD3 | |
| SCHEMBL10949210 | 0.81 | CHRM5 (0.54) | CYP1A2CHRM5ADRA2CHRH3 | |
| SCHEMBL10153844 | 0.81 | CYP1A2 (0.54) | CYP1A2CHRM5ADRA2CHRH3CARM1 | |
| SCHEMBL42023 | 0.81 | CYP1A2 (0.41) | CYP1A2CHRM5ADRA2C | |
| SCHEMBL30340999 | 0.79 | CHRM5 (0.58) | CYP1A2CHRM5ADRA2CHRH3 | |
| SCHEMBL12945 | 0.79 | CHRM5 (0.58) | CYP1A2CHRM5ADRA2CHRH3 | |
| SCHEMBL3218288 | 0.79 | CHRM5 (0.58) | CYP1A2CHRM5ADRA2CHRH3 | |
| SCHEMBL2249609 | 0.77 | CHRM5 (0.62) | CHRM5ADRA2CHRH3SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076503-B1 | C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2013-07-17 | — | — | EP | disclosed |
| EP-2465504-A1 | Novel 2,3-diamino-quinazolinone derivatives and their medical use | NeuroSearch A/S (DK) | 2012-06-20 | — | — | EP | disclosed |
| US-8178544-B2 | 2, 3-diamino-quinazolinone derivatives and their medical use | NEUROSEARCH A/S (DK) | 2012-05-15 | — | — | US | disclosed |
| US-7973012-B2 | C-phenyl glycitol compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20100160315-A1 | NOVEL 2, 3-DIAMINO-QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | NEURO SEARCH A/S (DK) | 2010-06-24 | — | — | US | disclosed |
| US-20100022460-A1 | C-PHENYL GLYCITOL COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-2076503-A2 | C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2009-07-08 | — | — | EP | disclosed |
| WO-2007136116-A2 | C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022460-A1 | C-PHENYL GLYCITOL COMPOUND | SLC5A1, SLC5A2, SLC2A1 | CYP1A2 1108/4885CHRM5 2266/4885ADRA2C 746/4885 |
| US-20100160315-A1 | NOVEL 2, 3-DIAMINO-QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | KCNJ2, KCNN3, KCNK17 | CYP1A2 1972/4885CHRM5 266/4885ADRA2C 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.